...
首页> 外文期刊>Cornea >A fibrin-based bioengineered ocular surface with human corneal epithelial stem cells.
【24h】

A fibrin-based bioengineered ocular surface with human corneal epithelial stem cells.

机译:一种基于纤维蛋白的生物工程化眼表,具有人类角膜上皮干细胞。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The purpose of the investigation was to prepare a bioengineered ocular surface tissue replacement consisting of (presumed) human corneal epithelial stem cells in a cross-linked fibrin gel for potential transplant. METHODS: Presumed human epithelial stem cells were harvested, isolated, and cultivated as previously described from adult donor corneas obtained from a tissue and organ bank. The cultured corneal epithelial stem cells were suspended in a fibronectin/fibrin gel cross-linked by factor XIII. Plasma components were derived from a fibrinogen-rich cryoprecipitate of human plasma. Suspended cells proliferated in the fibrin gel, giving rise to colonies that eventually coalesced to near confluence over the 15 days of cultivation. The gels were sectioned and immunostained for keratin 3 (AE5) and keratin 19. RESULTS: The fibrin gel product with corneal stem cells was easily manageable and maneuverable. Addition of the protease inhibitor aprotinin to the incubation medium prevented gel degradation; once it was removed, gels disintegrated within 24 hours. All of the cells cultivated in the fibrin gel stained positively for keratin 3 (AE5), indicating differentiation along the corneal epithelium lineage. Cells located in the center of the colonies were keratin 19-positive, suggesting a more primitive cell type. Growth kinetics were documented. CONCLUSIONS: A bioengineered ocular surface with a combination of presumed corneal epithelial stem cells in a cross-linked fibrin gel represents a potential improvement in current attempts to create a transportable, pliable, and stable tissue replacement. Since both the cells and the plasma components of the fibrin gel are of human origin, this technique provides the potential for a totally autologous bioengineered replacement tissue.
机译:目的:研究的目的是准备一种生物工程化的眼表组织替代物,该替代物由(假定的)人角膜上皮干细胞在交联的纤维蛋白凝胶中组成,以进行潜在的移植。方法:如先前所述,从从组织和器官库获得的成年供体角膜中收集,分离和培养假定的人上皮干细胞。将培养的角膜上皮干细胞悬浮在通过因子XIII交联的纤连蛋白/纤维蛋白凝胶中。血浆成分来源于人血浆中富含纤维蛋白原的冷沉淀。悬浮的细胞在纤维蛋白凝胶中增殖,从而形成集落,最终在培养的15天中融合到几乎汇合的位置。将凝胶切成薄片并对角蛋白3(AE5)和角蛋白19进行免疫染色。结果:带有角膜干细胞的纤维蛋白凝胶产品易于操作和操纵。将蛋白酶抑制剂抑肽酶添加到温育培养基中可防止凝胶降解。一旦将其移除,凝胶将在24小时内崩解。在纤维蛋白凝胶中培养的所有细胞角蛋白3(AE5)染色呈阳性,表明沿角膜上皮谱系分化。位于菌落中心的细胞角蛋白19阳性,表明细胞类型更为原始。记录了生长动力学。结论:在交联的纤维蛋白凝胶中结合了假定的角膜上皮干细胞的生物工程性眼表代表了当前尝试产生可运输,柔韧且稳定的组织替代物的潜在改进。由于纤维蛋白凝胶的细胞和血浆成分都是人类来源的,因此该技术为完全自体的生物工程替代组织提供了潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号